Intetumumab
Modify Date: 2024-04-08 18:06:24
Intetumumab structure
|
Common Name | Intetumumab | ||
|---|---|---|---|---|
| CAS Number | 725735-28-4 | Molecular Weight | 145.6 (kDa) | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IntetumumabIntetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer[1][2]. |
| Name | Intetumumab |
|---|
| Description | Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Intetumumab (CNTO 95; 0-5 μg/mL; 20 分钟; USPC-ARK-3 细胞) 抑制整合素介导的 USPC 细胞粘附于玻璃连素底物，并抑制血清诱导的 USPC 细胞迁移[1]。 |
| In Vivo | Intetumumab (CNTO 95; 10 mg/kg; i.p.; 雄性裸大鼠) 抑制肿瘤生长，抑制 A549 肿瘤的自发肺转移，减少发生肺转移的大鼠数量和每个肺的转移病灶数量[2]。 Animal Model: Male nude rats with lung metastasis models (5-6 weeks old and 150-200 g)[2] Dosage: 10 mg/kg Administration: Intraperitoneal injection; once a week for 60 days Result: Had the total tumor response rates (CR and PR) was 33% in A549 tumor model. Developed lung metastases only 4 of 9 rats. |
| References |
| Molecular Weight | 145.6 (kDa) |
|---|